Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 1
2010 1
2011 3
2012 3
2013 2
2014 2
2015 2
2016 1
2017 2
2018 3
2019 1
2020 1
2021 4
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.
Arenal Á, Ávila P, Jiménez-Candil J, Tercedor L, Calvo D, Arribas F, Fernández-Portales J, Merino JL, Hernández-Madrid A, Fernández-Avilés FJ, Berruezo A. Arenal Á, et al. Among authors: fernandez portales j. J Am Coll Cardiol. 2022 Apr 19;79(15):1441-1453. doi: 10.1016/j.jacc.2022.01.050. J Am Coll Cardiol. 2022. PMID: 35422240 Free article. Clinical Trial.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
Bayesian analysis of the Substrate Ablation vs. Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia trial.
Ávila P, Berruezo A, Jiménez-Candil J, Tercedor L, Calvo D, Arribas F, Fernández-Portales J, Merino JL, Hernández-Madrid A, Fernández-Avilés F, Arenal Á. Ávila P, et al. Among authors: fernandez portales j. Europace. 2023 Jul 4;25(7):euad181. doi: 10.1093/europace/euad181. Europace. 2023. PMID: 37366571 Free PMC article. Clinical Trial.
Effects of Cardiac Stem Cell on Postinfarction Arrhythmogenic Substrate.
Arenal Á, Ríos-Muñoz GR, Carta-Bergaz A, Ruiz-Hernández PM, Pérez-David E, Crisóstomo V, Loughlin G, Sanz-Ruiz R, Fernández-Portales J, Acosta A, Báez-Díaz C, Blanco-Blázquez V, Ledesma-Carbayo MJ, Pareja M, Fernández-Santos ME, Sánchez-Margallo FM, Casado JG, Fernández-Avilés F. Arenal Á, et al. Among authors: fernandez portales j. Int J Mol Sci. 2022 Dec 19;23(24):16211. doi: 10.3390/ijms232416211. Int J Mol Sci. 2022. PMID: 36555857 Free PMC article.
Outcomes and regional differences in practice in a worldwide coronary stent registry.
Cimci M, Polad J, Mamas M, Iniguez-Romo A, Chevalier B, Abhaichand R, Aminian A, Roguin A, Maluenda G, Angioi M, Cassel G, Kuramitsu S, Jacobs L, Debrus R, Malik F, Hildick-Smith D, Laanmets P, Roffi M; e-ULTIMASTER investigators. Cimci M, et al. Heart. 2022 Jul 27;108(16):1310-1318. doi: 10.1136/heartjnl-2021-320116. Heart. 2022. PMID: 35012960 Free PMC article.
Right versus left radial artery access for coronary procedures: an international collaborative systematic review and meta-analysis including 5 randomized trials and 3210 patients.
Biondi-Zoccai G, Sciahbasi A, Bodí V, Fernández-Portales J, Kanei Y, Romagnoli E, Agostoni P, Sangiorgi G, Lotrionte M, Modena MG. Biondi-Zoccai G, et al. Among authors: fernandez portales j. Int J Cardiol. 2013 Jul 1;166(3):621-6. doi: 10.1016/j.ijcard.2011.11.100. Epub 2011 Dec 20. Int J Cardiol. 2013. PMID: 22192284 Free article. Review.
34 results